Tyra Biosciences (NASDAQ:TYRA) Price Target Raised to $53.00

Tyra Biosciences (NASDAQ:TYRA) had its price objective lifted by Wedbush from $37.00 to $53.00 in a research report released on Friday morning, MarketBeat.com reports. The firm currently has an outperform rating on the stock.

Other analysts have also recently issued reports about the company. Wall Street Zen cut Tyra Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 24th. William Blair assumed coverage on shares of Tyra Biosciences in a report on Tuesday, February 10th. They issued an “outperform” rating for the company. Barclays started coverage on shares of Tyra Biosciences in a research report on Tuesday, January 27th. They set an “overweight” rating for the company. Jefferies Financial Group lifted their target price on shares of Tyra Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, February 3rd. Finally, Piper Sandler boosted their target price on shares of Tyra Biosciences from $33.00 to $42.00 and gave the stock an “overweight” rating in a research note on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Tyra Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $39.83.

Tyra Biosciences Stock Down 4.1%

Shares of Tyra Biosciences stock opened at $27.99 on Friday. Tyra Biosciences has a twelve month low of $6.42 and a twelve month high of $33.99. The business has a 50-day moving average price of $27.66 and a 200 day moving average price of $18.97. The firm has a market cap of $1.49 billion, a PE ratio of -14.97 and a beta of 1.07.

Insiders Place Their Bets

In related news, Director Robert J. More sold 246,871 shares of the business’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $20.25, for a total transaction of $4,999,137.75. Following the transaction, the director directly owned 3,833,425 shares in the company, valued at approximately $77,626,856.25. The trade was a 6.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 15.20% of the company’s stock.

Institutional Investors Weigh In On Tyra Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Commodore Capital LP lifted its position in Tyra Biosciences by 8.9% during the third quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock worth $47,216,000 after buying an additional 275,000 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Tyra Biosciences by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company’s stock worth $21,267,000 after acquiring an additional 118,492 shares during the period. Balyasny Asset Management L.P. raised its holdings in shares of Tyra Biosciences by 45.1% during the 3rd quarter. Balyasny Asset Management L.P. now owns 846,585 shares of the company’s stock worth $11,844,000 after acquiring an additional 263,199 shares during the period. Sio Capital Management LLC boosted its position in shares of Tyra Biosciences by 94.5% during the 2nd quarter. Sio Capital Management LLC now owns 810,274 shares of the company’s stock valued at $7,754,000 after acquiring an additional 393,657 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Tyra Biosciences by 74.9% in the fourth quarter. State Street Corp now owns 749,463 shares of the company’s stock valued at $19,703,000 after purchasing an additional 320,991 shares during the period. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.